Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

BACKGROUND: Low efficacy of miltefosine in the treatment of visceral leishmaniasis was recently observed in Eastern Africa. OBJECTIVES: To describe the pharmacokinetics and establish a pharmacokinetic/pharmacodynamic relationship for miltefosine in Eastern African patients with visceral leishmaniasi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Antimicrob Chemother
Autors principals: Dorlo, Thomas P C, Kip, Anke E, Younis, Brima M, Ellis, Sally J, Alves, Fabiana, Beijnen, Jos. H, Njenga, Simon, Kirigi, George, Hailu, Asrat, Olobo, Joseph, Musa, Ahmed M, Balasegaram, Manica, Wasunna, Monique, Karlsson, Mats O, Khalil, Eltahir A G
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890687/
https://ncbi.nlm.nih.gov/pubmed/28961737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx283
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars